Company Overview

ULTRAGENYX PHARMACEUTICAL INC.

RARE
Annual
Revenue vs. Cost of Revenue
Revenue Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses Operating Income
Net Income
Net Income
Revenue
673M
2025 FY
Net Income
-575M
2025 FY
Shares Outstanding
99M
2025 FY
EPS
-5.83USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1515673
Exchange
Nasdaq
Location
US